ClinicalTrials.gg
CompletedNCT07276009ProPepsisUpdated Sep 25, 2026

Probiotics in Functional Dyspepsia

An interventional study of Lactobacillus and Maltodextrin (Placebo) in Functional Dyspepsia, sponsored by Nordic Biotic Sp. z o.o.. Completed at 1 site in Ukraine. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 25, 2026Now CompletedFirst site in Ukraine+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are:

  • Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation?
  • Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia.

Participants will:

  • Take one capsule of the probiotic or placebo once daily before meals for 60 days
  • Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months
  • Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months
  • Attend scheduled study visits for checkups and assessments
02

Conditions studied

  • Functional Dyspepsia

Browse trials for

03

In context

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

This study's enrollment of 60 is below the median of 88 across 303 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Nordic Biotic Sp. z o.o. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years
  2. Diagnosis of Functional Dyspepsia based on Rome IV criteria, with symptoms present for at least 3 months, and symptom onset at least 6 months before diagnosis, including:

    • Postprandial fullness
    • Early satiation
    • Epigastric pain or burning
    • (with no evidence of structural disease explaining symptoms)
  3. Moderate to severe symptom severity at baseline, as defined by a validated scale (e.g., NDI or global symptom score)
  4. Normal upper GI endoscopy within the last 12 months (or at screening), excluding structural disease (e.g., peptic ulcer, )
  5. Negative for H. pylori (either previously treated successfully or tested negative within study screening)
  6. Ability and willingness to provide and comply with study procedures
  7. Stable medication use, if any, for at least 4 weeks before screening (e.g., PPIs, antidepressants, laxatives)

Exclusion criteria

Exclusion Criteria:

  1. Evidence of structural GI disease (e.g., peptic ulcer, gastric cancer, celiac disease) on recent or screening endoscopy
  2. History of gastrointestinal surgery affecting stomach or small intestine (except appendectomy or cholecystectomy)
  3. Positive test for H. pylori during screening (or untreated known infection)
  4. Current or recent use (within 4 weeks) of antibiotics, pre-, pro- or postbiotics, unless part of study protocol
  5. Use of medications affecting GI motility (e.g., prokinetics, opioids, anticholinergics) within 2-4 weeks before enrollment
  6. Overlap with other functional GI disorders (except IBS) if they are the dominant complaint, unless your protocol allows overlap
  7. psychiatric illness (e.g., major depression, schizophrenia) that may interfere with symptom reporting or adherence
  8. Severe systemic or metabolic disease (e.g., uncontrolled diabetes, renal or hepatic failure)
  9. Pregnancy or lactation, or intention to become pregnant during the study period
  10. Participation in another clinical trial within the past 3 months
  11. Known allergy or intolerance to study product components
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Probiotic group

    L. rhamnosus LR110, B. lactis BI040, B. breve BB010, L. paracasei LPC100, L. acidophilus LA120, L. casei LR130, L. plantarum LP140, S. thermophilus ST250, B. longum BL020, B. bifidum BF030 5 billion CFU one time daily for 60 days

    Other: Lactobacillus

  • Placebo comparator
    Placebo group

    Product with excepients without probiotic bacteria one time daily for 60 days

    Other: Maltodextrin (Placebo)

Interventions

  • OtherLactobacillus

    5 billion CFU of lactobacilus ans streptococci once daily for 60 days

  • OtherMaltodextrin (Placebo)

    Placebo capsules will be given one a day for 60 days

06

What researchers measure

Primary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale

    Time frame: 30 and 60 days

07

Study locations

1 site
  • Primary Health Care Center No. 2 of Vinnytsia
    Vinnytsia, 21050, Ukraine
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in May 2026, 3 months.

Of 79 interventional studies with no phase under Dyspepsia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 3 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → May 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 10, 2025
StartActual
Jan 15, 2026
Primary completionActual
May 1, 2026was Mar 2026
CompletionActual
May 23, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Sep 25, 2026
Sites
1 site added — first site in Ukraine
Show site
  • Primary Health Care Center No. 2 of Vinnytsia · Vinnytsia, Ukraine
Sep 25, 2026
Start date
Jan 5, 2026→Jan 15, 2026 (actual)
Sep 25, 2026
Primary completion
Mar 1, 2026→May 1, 2026 (actual)
Sep 25, 2026
Study completion
May 1, 2026→May 23, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Completed
    1 site added — first site in Ukraine
    Show site
    • Primary Health Care Center No. 2 of Vinnytsia · Vinnytsia, Ukraine
    Start date Jan 5, 2026→Jan 15, 2026 (now actual)
    Primary completion Mar 1, 2026→May 1, 2026 (now actual)
    Study completion May 1, 2026→May 23, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07276009
Lead sponsor
Nordic Biotic Sp. z o.o.
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Jan 15, 2026
Primary completion
May 1, 2026
Completion
May 23, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion